Síndrome metabólico en mujeres en etapa reproductiva y de climaterio y su asociación con riesgo cardiovascular

Autores/as

DOI:

https://doi.org/10.59169/pentaciencias.v5i3.574

Palabras clave:

Obesidad; dislipemia; perimenopausia; riesgo cardiometabólico; biomarcadores.

Resumen

El síndrome metabólico es un grupo de factores de riesgo cardiometabólicos que incluyen obesidad central, resistencia a la insulina, dislipidemia e hipertensión. El objetivo de esta investigación fue analizar el síndrome metabólico en mujeres en etapa reproductiva y de climaterio y su asociación con riesgo cardiovascular. Se realizó un estudio descriptivo con diseño documental consultando en las siguientes bases de datos: PubMed, ScienceDirect, Dialnet, Scielo y Google Scholar. Se encontró que en la actualidad los principales biomarcadores sanguíneos asociados al síndrome metabólico y al riesgo de enfermedad cardiovascular son: adiponectina, leptina, relación leptina/adiponectina, factor de necrosis tumoral alfa, interleucina-6, pentraxina-3, grelina, y la lipoproteína lipasa oxidada, los cuales juegan un papel determinante en la fisiopatología de la ECV y del síndrome metabólico. La prevalencia de síndrome metabólico es mayor en mujeres en etapa climatérica que en etapa reproductiva. En América la prevalencia promedio en mujeres en etapa climatérica es del 51.3% vs 31.38 en etapa reproductiva; en Europa 24.3% vs 13.45; África: 34.53 vs 13.97 y Asia: 27.38 vs 16.78 respectivamente. En conclusión, los resultados de esta investigación sugieren que el síndrome metabólico es una condición estrechamente relacionada con el estado hormonal de la mujer, siendo más prevalente en la etapa climatérica y fuertemente asociado al riesgo cardiovascular.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Adejumo, E. N., Adejumo, A. O., Enitan, S. S., Ekun, A. O., Azenabor, A., Adebola, O. K., & Ogundahunsi, O. A. (2019). Leptin: Adiponectin ratio discriminated the risk of metabolic syndrome better than adiponectin and leptin in Southwest Nigeria. Diabetes & Metabolic Syndrome, 13(3), 1845–1849. https://doi.org/10.1016/J.DSX.2019.04.008

Adejumo, O., Akinbodewa, A. A., Ogunleye, A., Okaka, E. I., Lamidi, O., & Akinbo, E. (2020). Metabolic Syndrome and Atherosclerotic Cardiovascular Risk in a Population Of Market Women in a Semi-Urban Town, South-West Nigeria. West African Journal of Medicine, 37(6), 666–670. https://europepmc.org/article/med/33185264

Anagnostis, P., Paschou, S. A., Katsiki, N., Krikidis, D., Lambrinoudaki, I., & Goulis, D. G. (2018). Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now? Current Vascular Pharmacology, 17(6), 564–572. https://doi.org/10.2174/1570161116666180709095348

Borthakur, A., D Prabhu, Y., & Valsala Gopalakrishnan, A. (2020). Role of IL-6 signalling in Polycystic Ovarian Syndrome associated inflammation. En Journal of Reproductive Immunology (Vol. 141, p. 103155). Elsevier. https://doi.org/10.1016/j.jri.2020.103155

Bovolini, A., Garcia, J., Andrade, M. A., & Duarte, J. A. (2021). Metabolic Syndrome Pathophysiology and Predisposing Factors. International Journal of Sports Medicine, 42(3), 199–214. https://doi.org/10.1055/A-1263-0898/ID/R8170-0025

Chaves Pereira Reis, V. M., Santos Brant Rocha, J., Fonseca, A. A., Ferreira Freitas, R., Araújo Passos, B. M., Perim Baldo, M., Silveira Freire, R., Veloso Reis, G. C., Piana De Oliveira, F. S. L., De Magalhães, T. A., & Silveira, M. F. (2021). A Comparison of the Prevalence of Metabolic Syndrome According to Different Definitions in Climacteric Women. Metabolic Syndrome and Related Disorders, 19(8), 436–442. https://doi.org/10.1089/met.2020.0143

Chedraui, P., & Pérez-López, F. R. (2019). Metabolic syndrome during female midlife: what are the risks? En Climacteric (Vol. 22, Número 2, pp. 127–132). Taylor & Francis. https://doi.org/10.1080/13697137.2018.1561666

Chedraui, Peter, Pérez-López, F. R., Hidalgo, L., Villacreses, D., Domínguez, A., Escobar, G. S., Genazzani, A. R., & Simoncini, T. (2014). Evaluation of the presence and severity of menopausal symptoms among postmenopausal women screened for the metabolic syndrome. Gynecological Endocrinology, 30(12), 918–924. https://doi.org/10.3109/09513590.2014.971236

Choi, B. J., Heo, J. H., Choi, I. S., Lee, S. W., Kim, H. S., Lee, J. W., & Cha, T. J. (2012). Hypoadiponectinemia in Patients With Paroxysmal Atrial Fibrillation. Korean Circulation Journal, 42(10), 668–673. https://doi.org/10.4070/KCJ.2012.42.10.668

da Silva, J. S., Montagnoli, T. L., de Sá, M. P. L., & Zapata-Sudo, G. (2022). Heart Failure in Menopause: Treatment and New Approaches. En International Journal of Molecular Sciences (Vol. 23, Número 23, p. 15140). Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ijms232315140

Enciso Higueras, J., Cortés Aguilera, A., Rodríguez Gómez, J., & Rey Luque, Ó. (2022). Prevalencia del Síndrome Metabólico en el ámbito laboral. Ene, 16(2), 1298. https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1988-348X2022000200005&lng=es.

Finicelli, M., Squillaro, T., Di Cristo, F., Di Salle, A., Melone, M. A. B., Galderisi, U., & Peluso, G. (2019). Metabolic syndrome, Mediterranean diet, and polyphenols: Evidence and perspectives. Journal of Cellular Physiology, 234(5), 5807–5826. https://doi.org/10.1002/JCP.27506

Fu, Y. (2014). Adiponectin Signaling and Metabolic Syndrome. Progress in Molecular Biology and Translational Science, 121, 293–319. https://doi.org/10.1016/B978-0-12-800101-1.00009-0

García, M. J., Sosa, L., Adorno, R., González, L. K., & Bataglia, V. (2018). Prevalencia del Síndrome Metabólico en pacientes internadas en el Servicio de Ginecología del Hospital Central. Instituto de Previsión Social, Enero-Junio 2017. Revista de salud publica del Paraguay, 8(1), 40–43. https://doi.org/10.18004/rspp.2018.junio.40-43

Gersh, F. L. (2020). Benefits of estrogen in cardiovascular diseases. Progress in Cardiovascular Diseases, 63(3), 392. https://doi.org/10.1016/J.PCAD.2020.03.008

Ghadge, A. A., Khaire, A. A., & Kuvalekar, A. A. (2018). Adiponectin: A potential therapeutic target for metabolic syndrome. Cytokine & Growth Factor Reviews, 39, 151–158. https://doi.org/10.1016/J.CYTOGFR.2018.01.004

Gupta, V., Mishra, S., Mishra, S., Kumar, S., & Gupta, V. (2018). Association of Leptin: Adiponectin ratio and metabolic risk markers in postmenopausal women. Immunology Letters, 196, 63–67. https://doi.org/10.1016/J.IMLET.2018.01.008

Harraqui, K., Oudghiri, D. E., Hannoun, Z., Mrabti, H. N., Aboulghras, S., Assaggaf, H. M., Rajab, B. S., Attar, A. A., Bouyahya, A., & Bour, A. (2022). Frequency of Metabolic Syndrome and Study of Anthropometric, Clinical and Biological Characteristics in Peri-and Postmenopausal Women in the City of Ksar El Kebir (Northern Morocco). International Journal of Environmental Research and Public Health, 19(10), 6109. https://doi.org/10.3390/ijerph19106109

Hormaza Angel, M. P., Lopera Valle, J. S., Massaro Ceballos, M. M., Rendón Pereira, G. J., & Campo Campo, N. (2014). Síndrome metabólico y riesgo cardiovascular en mujeres posmenopáusicas de una institución de primer nivel de Envigado (Colombia). Clinica e Investigacion en Ginecologia y Obstetricia, 41(4), 151–157. https://doi.org/10.1016/j.gine.2013.05.007

Hurtado-Martínez, L., Saldarriaga-Giraldo, C. I., Jaramillo-Jaramillo, L. I., Hormaza-Ángel, M. P., Hurtado-Martínez, L., Saldarriaga-Giraldo, C. I., Jaramillo-Jaramillo, L. I., & Hormaza-Ángel, M. P. (2022). Riesgo cardiovascular durante la menopausia: una visión del cardiólogo y del ginecólogo. Revista Colombiana de Cardiología, 29(1), 7–15. https://doi.org/10.24875/RCCAR.21000101

Hyvärinen, M., Juppi, H. K., Taskinen, S., Karppinen, J. E., Karvinen, S., Tammelin, T. H., Kovanen, V., Aukee, P., Kujala, U. M., Rantalainen, T., Sipilä, S., & Laakkonen, E. K. (2022). Metabolic health, menopause, and physical activity—a 4-year follow-up study. International Journal of Obesity, 46(3), 544–554. https://doi.org/10.1038/s41366-021-01022-x

Ibrahim, M. K., & Alobaidi, A. H. A. (2021). Evaluation of the Role of Ghrelin and Leptin as Biochemical Markers in Female with Polycystic Ovarian Syndrome. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 20(4), 373–379. https://doi.org/10.2174/1871523020666210422132618

Iso, H., Cui, R., Takamoto, I., Kiyama, M., Saito, I., Okamura, T., Miyamoto, Y., Higashiyama, A., Kiyohara, Y., Ninomiya, T., Yamada, M., Nakagawa, H., Sakurai, M., Shimabukuro, M., Higa, M., Shimamoto, K., Saito, S., Daimon, M., Kayama, T., … Kadowaki, T. (2021). Risk classification for metabolic syndrome and the incidence of cardiovascular disease in japan with low prevalence of obesity: A pooled analysis of 10 prospective cohort studies. Journal of the American Heart Association, 10(23), 20760. https://doi.org/10.1161/JAHA.121.020760

Jeenduang, N., Trongsakul, R., Inhongsa, P., & Chaidach, P. (2014). The prevalence of metabolic syndrome in premenopausal and postmenopausal women in Southern Thailand. Gynecological Endocrinology, 30(8), 573–576. https://doi.org/10.3109/09513590.2014.907261

Jeong, H. G., & Park, H. (2022). Metabolic Disorders in Menopause. En Metabolites (Vol. 12, Número 10, p. 954). Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/metabo12100954

Joon Cho, G., Hyun Lee, J., Tae Park, H., Ho Shin, J., Cheol Hong, S., Kim, T., Young Hur, J., Wan Lee, K., Kyun Park, Y., & Haeng Kim, S. (2008). Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause (New York, N.Y.), 15(3), 524–529. https://doi.org/10.1097/GME.0B013E3181559860

Karamfilova, V., Assyov, Y., Nedeva, I., Gateva, A., Ivanova, I., Cherkezov, N., Mateva, L., & Kamenov, Z. (2022). Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 20(2), 132–136. https://doi.org/10.1089/met.2021.0086

Kardas, F., Akın, L., Kurtoglu, S., Kendirci, M., & Kardas, Z. (2015). Plasma Pentraxin 3 as a Biomarker of Metabolic Syndrome. Indian Journal of Pediatrics, 82(1), 35–38. https://doi.org/10.1007/S12098-014-1542-0/METRICS

Lambrinoudaki, I., Kazani, A., Armeni, E., Rizos, D., Augoulea, A., Kaparos, G., Alexandrou, A., Georgiopoulos, G., Kanakakis, I., & Stamatelopoulos, K. (2018). The metabolic syndrome is associated with carotid atherosclerosis and arterial stiffness in asymptomatic, nondiabetic postmenopausal women. Gynecological Endocrinology, 34(1), 78–82. https://doi.org/10.1080/09513590.2017.1344208

Macut, D., Ognjanović, S., Ašanin, M., Krljanać, G., & Milenković, T. (2021). Metabolic Syndrome and Myocardial Infarction in Women. Current Pharmaceutical Design, 27(36), 3786–3794. https://doi.org/10.2174/1381612827666210610114029

Molina Salazar, D., & Muñoz Gomez, D. (2018). Síndrome metabólico en la mujer. Revista Colombiana de Cardiología, 25(1), 21–29.

Moon, Y. S., Kim, D. H., & Song, D. K. (2004). Serum tumor necrosis factor-α levels and components of the metabolic syndrome in obese adolescents. Metabolism, 53(7), 863–867. https://doi.org/10.1016/J.METABOL.2004.02.007

Moore, K. J., & Shah, R. (2020). Introduction to the Obesity, Metabolic Syndrome, and CVD Compendium. Circulation Research, 126(11), 1475–1476. https://doi.org/10.1161/CIRCRESAHA.120.317240

Muchanga Sifa, M. J., Lepira, F. B., Longo, A. L., Sumaili, E. K., Makulo, J. R., Mbelambela, E. P., Tozin, R., Ngatu, N. R., & Suganuma, N. (2014). Prevalence and predictors of metabolic syndrome among Congolese pre-and postmenopausal women. Climacteric, 17(4), 442–448. https://doi.org/10.3109/13697137.2013.856403

Mumusoglu, S., & Yildiz, B. O. (2018). Metabolic Syndrome During Menopause. Current Vascular Pharmacology, 17(6), 595–603. https://doi.org/10.2174/1570161116666180904094149

Ntzouvani, A., Fragopoulou, E., Panagiotakos, D., Pitsavos, C., & Antonopoulou, S. (2016). Reduced circulating adiponectin levels are associated with the metabolic syndrome independently of obesity, lipid indices and serum insulin levels: A cross-sectional study. Lipids in Health and Disease, 15(1), 1–14. https://doi.org/10.1186/S12944-016-0311-7/TABLES/6

Obradovic, M., Sudar-Milovanovic, E., Soskic, S., Essack, M., Arya, S., Stewart, A. J., Gojobori, T., & Isenovic, E. R. (2021). Leptin and Obesity: Role and Clinical Implication. Frontiers in Endocrinology, 12, 563. https://doi.org/10.3389/fendo.2021.585887

Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017). IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40–50. https://doi.org/10.1016/j.diabres.2017.03.024

Oh, G. C., Kang, K. S., Park, C. S., Sung, H. K., Ha, K. H., Kim, H. C., Park, S., Ihm, S. H., & Lee, H. Y. (2018). Metabolic syndrome, not menopause, is a risk factor for hypertension in peri-menopausal women. Clinical Hypertension, 24(1), 1–8. https://doi.org/10.1186/S40885-018-0099-Z/TABLES/3

Pacheco Armenta, M., & Jaquez Torres, J. (2017). Prevalencia de síndrome metabólico en la consulta externa. Rev Sanid Milit Mex, 71(5), 264–275. www.sanidadmilitar.org.mxartículoorignal

Pérez-Galarza, J., Baldeón, L., Franco, O. H., Muka, T., Drexhage, H. A., Voortman, T., & Freire, W. B. (2021). Prevalence of overweight and metabolic syndrome, and associated sociodemographic factors among adult Ecuadorian populations: the ENSANUT-ECU study. Journal of Endocrinological Investigation, 44(1), 63–74. https://doi.org/10.1007/S40618-020-01267-9/FIGURES/5

Pucci, G., Alcidi, R., Tap, L., Battista, F., Mattace-Raso, F., & Schillaci, G. (2017). Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. En Pharmacological Research (Vol. 120, pp. 34–42). Academic Press. https://doi.org/10.1016/j.phrs.2017.03.008

Pulkkinen, L., Ukkola, O., Kolehmainen, M., & Uusitupa, M. (2010). Ghrelin in diabetes andmetabolic syndrome. En International Journal of Peptides (Vol. 2010). Hindawi Limited. https://doi.org/10.1155/2010/248948

Raczkiewicz, D., Owoc, A., Wierzbińska-Stępniak, A., & Bojar, I. (2018). Metabolic syndrome in peri - and postmenopausal women performing intellectual work. Annals of Agricultural and Environmental Medicine, 25(4), 610–615. https://doi.org/10.26444/AAEM/74451

Rivas-Urbina, A., Benitez, S., Perez, A., & Sanchez-Quesada, J. L. (2018). Modified low-density lipoproteins as biomarkers in diabetes and metabolic syndrome. Frontiers in Bioscience - Landmark, 23(7), 1220–1240. https://doi.org/10.2741/4640/PDF

Rodrigues, A. D., Theodoro, H., Mendes, K. G., Paniz, V. M., De Lorenzi, D., & Anselmo Olinto, M. T. (2013). Factors associated with metabolic syndrome in climacteric women of southern Brazil. Climacteric, 16(1), 96–103. https://doi.org/10.3109/13697137.2012.659099

Saklayen, M. G. (2018). The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports, 20(2), 1–8. https://doi.org/10.1007/S11906-018-0812-Z/METRICS

Samson, S. L., & Garber, A. J. (2014). Metabolic syndrome. Endocrinology and Metabolism Clinics of North America, 43(1), 1–23. https://doi.org/10.1016/J.ECL.2013.09.009

Samy, K., Porwal, Y. C., & Yadav, A. (2022). Evaluation of Interleukin 6(Il-6), Tumor Necrosis Factor Alpha (Tnf-α) and Paraoxonase 1(Pon 1) in Obese and Non-Obese Metabolic Syndrome. The Journal of the Association of Physicians of India, 70(4), 11–12. https://pubmed.ncbi.nlm.nih.gov/35443473/

Santilli, F., D’Ardes, D., Guagnano, M. T., & Davi, G. (2017). Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach. Current Medicinal Chemistry, 24(24). https://doi.org/10.2174/0929867324666170710121145

Setroame, A. M., Kormla Affrim, P., Abaka-Yawson, A., Kwadzokpui, P. K., Eyram Adrah, F., Bless, H., Mohammed, L., Bawah, A. T., & Alidu, H. W. (2020). Prevalence of Metabolic Syndrome and Nonalcoholic Fatty Liver Disease among Premenopausal and Postmenopausal Women in Ho Municipality: A Cross-Sectional Study. BioMed Research International, 20(2). https://doi.org/10.1155/2020/2168381

Stanhewicz, A. E., Wenner, M. M., & Stachenfeld, N. S. (2018). Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan. En American Journal of Physiology - Heart and Circulatory Physiology (Vol. 315, Número 6, pp. H1569–H1588). American Physiological Society. https://doi.org/10.1152/ajpheart.00396.2018

Stevenson, J. C., Tsiligiannis, S., & Panay, N. (2018). Cardiovascular Risk in Perimenopausal Women. Current Vascular Pharmacology, 17(6), 591–594. https://doi.org/10.2174/1570161116666181002145340

Tadic, M., Cuspidi, C., Vasic, D., & Kerkhof, P. L. M. (2018). Cardiovascular implications of diabetes, metabolic syndrome, thyroid disease, and cardio-oncology in women. Advances in Experimental Medicine and Biology, 1065, 471–488. https://doi.org/10.1007/978-3-319-77932-4_29

Ullah, M. I., Alzahrani, B., Alsrhani, A., Atif, M., Alameen, A. A. M., & Ejaz, H. (2021). Determination of serum tumor necrosis factor-alpha (TNF-α) levels in metabolic syndrome patients from Saudi population. Pakistan Journal of Medical Sciences, 37(3), 700–705. https://doi.org/10.12669/PJMS.37.3.3897

Urina, J., Urina, J., Urina, T., Mantilla, M., Urina, T., & Galeano, M. (2018). La prevalencia del síndrome metabólico en mujeres postmenopáusicas. Revista Latinoamericana de Hipertensión, 13(4), 384–389. https://www.revhipertension.com/rlh_4_2018/15_prevalencia_sindrome_metabolico.pdf

Valdés, E., Castillo, Y., & Valdés, E. (2020). Etapas del climaterio y enfermedad cardiovascular en mujeres diabéticas de edad mediana. Revista Cubana de Endocrinología, 31(2), 1–13. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532020000200005

Vega, G. L., Wang, J., & Grundy, S. M. (2021). Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. Journal of Clinical Lipidology, 15(2), 255–265. https://doi.org/10.1016/j.jacl.2021.01.012

Zilberman, J. M. (2018). Menopausia: hipertension arterial y enfermedad vascular. Hipertensión y Riesgo Vascular, 35(2), 77–83. https://doi.org/10.1016/J.HIPERT.2017.11.001

Zlibut, A., Bocsan, I. C., Pop, R. M., Vesa, S. C., Bheecarry, K., Revnic, R., Cojan-Minzat, B., Lupu, S., Buzoianu, A. D., & Agoston-Coldea, L. (2019). Role of pentraxin-3 in risk assessment of patients with metabolic syndrome. Physiology International, 106(3), 283–293. https://doi.org/10.1556/2060.106.2019.18

Descargas

Publicado

2023-03-13

Cómo citar

Caicedo Loor, J. V., & Alcocer Diaz , S. . (2023). Síndrome metabólico en mujeres en etapa reproductiva y de climaterio y su asociación con riesgo cardiovascular . Revista Científica Arbitrada Multidisciplinaria PENTACIENCIAS, 5(3), 551–566. https://doi.org/10.59169/pentaciencias.v5i3.574

Número

Sección

Artículos de revisión